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ABSTRACT
Antibody-mediated rejection (AMR) is a relatively rare but severe complication in kidney transplantation 
associated with increased risk of graft loss. Diagnosis of acute and chronic AMR is based on typical 
histological hallmarks, deposition of C4d in peritubular capillaries and presence of donor-specific antibodies 
(DSA). Many novel and attractive treatment options have become available in recent years: antibody removal 
and production inhibition (plasmapheresis, IVIg), B cell depletion (rituximab), plasma cell depletion and 
apoptosis (bortezomib), and complement activation inhibition (eculizumab). Standard therapy is based on 
PP and IVIg. Preliminary results with new agents are encouraging but require randomised clinical trials and 
long-term follow-up. 
Keywords: Kidney transplantation, antibody-mediated rejection, donor-specific antibodies, management of 
antibody-mediated rejection, IVIg, plasmapheresis, bortezomib, rituximab, eculizumab.
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INTRODUCTION
The mechanism of organ transplant rejection may 
be cellular (T lymphocyte-mediated) or humoral – 
the latter being mediated by antibodies produced 
in response to donor-specific antigens exposed 
on endothelial cells of the allograft. For a long 
time, transplant specialists have focused on the 
diagnosis and treatment of cell-mediated reactions, 
even though the negative effects of alloantibodies 
in the transplanted organ have been identified by 
Patel and Terasaki as early as 1969.1 However, it was 
only in the last two decades that the diagnosis of 
antibody-mediated rejection (AMR) was rendered 
possible by the introduction of sensitive methods 
of detection of anti-human leukocyte antigen 
(HLA) antibodies, and most importantly, of donor-
specific antibodies, using synthetic antigen assays 
(Luminex) and C4d detection in graft tissue as 
a specific marker of complement activation. In 
1991, Feucht et al.2,3 described peritubular capillary 
C4d deposition in renal transplants, and in 1993 
postulated the association of this finding with graft 
loss. In 1999, Collins et al.4 reported a correlation 
between humoral rejection with peritubular capillary 
C4d deposition and the presence of circulating 
anti-donor antibodies in transplant recipients. C4d 
is a product of systemic breakdown of C4, a classic 
complement activation pathway component whose 
biological role is unclear. C4d has more stability 
than other complement components because it 
forms a covalent complex with the surface of the 
endothelium and the basement membrane; the 
time to breakdown is about 1-3 weeks. Identification 
of C4d deposition using immunofluorescence or 
immunoperoxidase assay marks a breakthrough 
in histopathologic diagnosis of kidney allografts, 
and peritubular capillary location of deposits is 
considered a highly specific marker of acute and 
chronic humoral rejection. C4d detection is currently 
a standard for histopathological diagnosis of kidney 
allografts.5 In the Banff classification, the term ‘acute 
antibody-mediated rejection’ appeared for the first 
time in 2003, and ‘chronic active antibody-mediated 
rejection’ was introduced in 2005 due to growing 
evidence for the role of humoral mechanisms in 
allograft damage. The current Banff classification 
adopted in 2009 includes diagnostic criteria for 
acute and chronic antibody mediated rejection.6 NEPHROLOGY  •  July 2013    EMJ EUROPEAN MEDICAL JOURNAL 41
THE ROLE OF ALLOANTIBODIES
Anti-HLA antibodies have been identified in 1% 
to 60% of recipients, depending on the tested 
population, time from transplantation, and to a 
significant extent, the sensitivity and specificity 
of detection methods. Donor-specific antibodies 
(DSA) developing de novo after transplantation 
are now considered as the principal factor in the 
pathogenesis of graft damage. De novo antibodies 
occur in the early post-transplantation period 
(within the first 3 months). They indicate a risk 
of acute or chronic AMR.7,8 The development 
of alloantibodies precedes the appearance of 
morphological and functional abnormalities of the 
graft, therefore early identification of possible AMR 
warrants DSA monitoring every 3 months during 
the  first-year  post-transplantation,  and  once  a                                                      
year thereafter.
Acute AMR may occur in the absence of detectable 
antibodies, if the antibodies are bound in the organ 
transplant. The incidence of acute AMR among 
kidney transplant recipients ranges from about 5-7% 
to 40-90% in non-sensitised and sensitised subjects, 
respectively. Acute AMR occurs most commonly 
as part of mixed cellular-humoral rejection (25%) 
and is rarely an isolated phenomenon. Chronic 
kidney transplant rejection manifests as slowly 
progressing functional deterioration that may be 
seen over several months, or even years. Clinical 
manifestations include proteinuria, hypertension 
and slowly progressing loss of glomerular filtration. 
Histopathology shows evidence of chronic transplant 
glomerulopathy (TG). Chronic humoral rejection is 
seen in 5-15% of protocol biopsies, and the onset is 
usually subclinical. TG has been reported in more 
than 40% of recipients with a history of acute AMR. 
Chronic transplant glomerulopathy is associated 
with poor outcome, which is even worse than that of 
interstitial fibrosis (IF)/tubular atrophy (TA).9,10
It is now widely considered that the principal cause 
of kidney transplant loss is not nephropathy, but 
an ongoing immunological process that can be 
described as chronic antibody-mediated rejection. 
Furthermore, it has been emphasised that modern 
immunosuppression regimens, which tend to 
minimise or discontinue calcineurin inhibitor (CNI), 
or glucocorticosteroids may be responsible for 
the development of chronic AMR. Chronic graft 
rejection is known to result from inadequate 
immunosuppression. The role of chronic humoral 
response in the pathogenesis of late transplant loss 
was confirmed in a US multicentre study (DeKAF 
Study – Long-term Deterioration of Kidney Allograft 
Function). In 173 recipients with late graft dysfunction 
(average of 7 years post-transplantation) who 
underwent graft biopsy, AMR correlates, such as 
C4d deposits in biopsy samples or serum DSA, 
were found in 57% of cases. In 2 years, the poorest 
outcome in terms of graft survival was seen in those 
patients who had both C4d and DSA, and the best 
in those with negative humoral reaction correlates. 
Signs of nephrotoxicity, if present, had no significant 
effect on graft survival.11
TREATMENT
Treatment of humoral-mediated acute graft 
rejection differs from that of cell-mediated rejection; 
it involves the elimination of circulating antibodies 
and suppression of antibody production by B 
lymphocytes or plasma cells. To date, no formal 
standards for the management of humoral-mediated 
acute graft rejection have been developed. 
Knowledge in this area is growing rapidly, and 
recent reports in the literature continue to enrich 
and broaden its scope. The pathogenesis of AMR 
forms the basis of proposed therapeutic regimens. 
DSA are produced by plasma cells which may be 
present in the pre-transplantation period or develop 
after transplantation from B lymphocytes (memory 
or naïve). T lymphocytes are necessary to initiate 
primary B cell-mediated response, leading to the 
development of plasma cells.12,13
Treatment Modalities in AMR Include:
•	 Elimination of circulating antibodies
o  Plasmapheresis (PP)
o  Immunoadsorption
•	 Suppression of remaining antibodies
o  IV infusions of immunoglobulins - IVIg
o  Mycophenolate mofetil (MMF)
•	 Blocking antibody production, B 
lymphocyte depletion
o  Glucocorticosteroids (GS)
o  Anti-CD20 antibody - rituximab
o  Anti-thymocyte globulin
o  Splenectomy
•	 Suppression of T cell response
o  Anti-thymocyte globulin
o  Mycophenolate mofetil (MMF) 
o  Calcineurin inhibitors (CNI)
•	 Plasmocyte depletion and apoptosis
o  Proteasome inhibitor - bortezomib
•	 Complement inhibition
o  Anti-C5 antibody - eculizumab
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State-of-the-art, promising therapies target 
plasma cells or the complement. Typically 
the  treatment  consists  in  combining  several                                                      
therapeutic approaches.
Plasmapheresis 
Plasmapheresis is the fastest and the most efficient 
way to eliminate DSA; 1 volume -1.5 volume of total 
plasma volume is exchanged using 5% albumin 
or fresh frozen plasma (FFP). Plasmapheresis is 
performed every other day until improvement in 
kidney function is obtained (usually five-seven 
procedures). Plasmapheresis has no inhibitory 
effect on antibody production, therefore it is usually 
combined with 100 mg/kg IVIg after each PP session 
(up to a total of 1 g/kg body weight) and 300-400 
mg/kg body weight (bw) for 1-2 days following 
the last PP. A combination of plasmapheresis and 
rituximab has been reported. Tacrolimus and MMF 
are recommended for primary immunosuppression 
due to their inhibitory effect on DSA production.
Human Immunoglobulins
The immunomodulatory activity of IgG is unknown. 
They are known to affect cell-mediated (T and B) 
immune response.
Proposed mechanisms of action of immunoglobulin:
•	 Anti-idiotypic antibodies neutralise 
circulating alloantibodies
•	 IVIg blocks T lymphocyte activation 
by interacting with the Fc receptor on 
antigen-presenting cells
•	 IVIg inhibits the activity of complement 
factors C3b and C4b
•	 IVIg inhibits cytokine secretion and activity
•	 IVIg inhibits the proliferation and 
activation of T and B lymphocytes
•	 IVIg inhibits epithelial cell activation
•	 Increase B lymphocyte apoptosis
High dose (1-2 g/kg bw) IgG should be used to achieve 
the desired therapeutic outcome. Non-randomised 
studies based on small patient populations, show 
combination therapy with PP+IVIg+rituximab proved 
more effective than IVIg alone in the treatment of 
acute AMR.14
Anti-CD20
Rituximab is a murine/human chimera, directed 
against the CD20 molecule located on B lymphocytes. 
It causes B cell lysis via antibody-dependent 
cytotoxicity (ADCC) or complement dependent 
cytotoxicity (CDC), and prompts B cell apoptosis. 
The target protein for rituximab is the CD20 antigen 
located on immature pre-B cells and mature B 
lymphocytes, but not on plasma cells. Intravenous 
administration of rituximab leads to rapid and 
sustained depletion of circulating and tissue-based 
B lymphocytes. B lymphocyte recovery starts as late 
as approximately 6 months following termination 
of therapy, and the B cell counts return to normal 
within 9-12 months. Genberg et al.15 investigated 
the effect of a single dose of rituximab on the B 
lymphocyte population in peripheral blood, kidney 
graft tissue and lymph nodes of 49 kidney transplant 
recipients. A single dose (375 mg/m2) of rituximab 
was used in combination with standard triple 
agent immunosuppression. Total B cell depletion in 
peripheral blood was found in 78% of patients. At 
15 months following administration of a single dose 
of rituximab, B lymphocytes were undetectable in 
peripheral blood and graft tissue (CD19 and CD20 
less than 5 cells/µl). They could not be completely 
eliminated from the lymph nodes, but their number 
was significantly reduced. Rituximab is licensed for 
the treatment of non-Hodgkin lymphomas and post-
transplant lymphoproliferative disease (PTLD). The 
efficacy of rituximab in the treatment of AMR was 
initially reported by Becker et al.,16 who used a single 
dose of rituximab (375 mg/m2) in renal transplant 
recipients and achieved remission in 24 patients. 
A number of reports in the literature support the 
efficacy of rituximab in the treatment of acute AMR, 
particularly in combination with plasmapheresis and 
glucocorticoid pulses. Kaposztas et al.17 described a 
retrospective cohort of 54 graft recipients with AMR 
(the largest reported cohort to date), who were 
treated with a combination of PP and rituximab 
or PP alone. After 24 months, graft survival was 
significantly better in the rituximab group (90% vs. 
60%). Lefaucher et al.18 reported significantly better 
outcomes in terms of 36-month graft survival (92% 
vs. 50%) in 12 recipients treated with PP, IVIg and 
rituximab in comparison with a historical control 
group who received IVIg monotherapy [18]. The 
posology and duration of rituximab therapy in 
kidney transplant recipients have not been defined. 
Most reports used a single dose, but three to five 
doses have been described as well. Prospective 
randomised studies and follow-up results are lacking, 
and benefits of rituximab in the treatment of AMR 
cannot be evaluated unequivocally in the setting of 
concurrent polytherapies. Note should be taken of 
late onset, severe infectious events that may occur 
3-4 months following administration of rituximab. It 
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measures against Pneumocystis infection and 
monitor cytomegalovirus (CMV) and BK virus (BKV) 
replication, as well as signs of bacterial and fungal 
infections. The principal limitation of rituximab is the 
lack of effect on DSA-producing plasma cells.
Anti-Thymocyte Globulin
Anti-thymocyte globulin (ATG) is a polyclonal 
antibody. Its beneficial effects, in terms of suppressing 
AMR, involve the following mechanisms of action:
•	 Inhibition of T-helper lymphocytes which 
are necessary for B lymphocyte activation
•	 Complement-dependent lysis of B 
lymphocytes
•	 Suppression of B lymphocyte proliferation
•	 Induction of B lymphocyte apoptosis
•	 Inhibition of co-stimulation molecules and 
cytokine production
Since acute graft rejection frequently occurs via 
a mixed mechanism, with a predominant cellular 
component, ATG is often used to treat this type of 
rejection in combination with glucocorticosteroids 
(GS) and plasmapheresis.19
Glucocorticosteroids 
Glucocorticosteroids are used as first-line therapy in 
acute graft rejection of any type. They are effective 
in T cell-mediated rejection, in mixed type rejection 
they act on the cell-mediated component, whereas 
in the humoral type they suppress B cell-mediated 
response by interacting with T-helper lymphocytes. 
Routine recommendations include pulses of 
methylprednisolone 250-500 mg for 3-5 days.
Mycophenolate Mofetil and Tacrolimus
MMF is an antiproliferative agent with an inhibitory 
effect on humoral response and antibody production. 
When used in combination with tacrolimus, MMF 
suppresses B cell-mediated response in AMR. In 
this context, MMF should not be co-administered 
with cyclosporine, as cyclosporine decreases 
exposure to MMF. Lederer et al.20 showed that in 
kidney transplant recipients, MMF decreases the 
levels of anti-class I and II HLA antibodies and DSA, 
particularly in patients who started MMF therapy 
from the day of transplantation. In all cases of AMR, it 
is recommended to use primary immunosuppression 
regimens involving tacrolimus and MMF.21
Eculizumab
An interesting therapeutic option may consist in 
suppressing the complement system. Eculizumab 
is a humanised antibody directed against C5 
complement protein, which inhibits the formation of 
the membrane attack complex (MAC, C5b-C9). MAC 
is a protein structure formed in terminal complement 
activation. Eculizumab induces accommodation of 
endothelial cells, reduces the formation of C5b-C9 
(MAC) deposits in the transplanted kidney. Stegall et 
al.22 reported the efficacy of eculizumab in 26 highly 
immunised patients with acute AMR. The incidence 
of AMR was significantly lower in the eculizumab 
group (7.7%) as compared to controls (41.2%); at 1 
year, transplant glomerulopathy (TG) developed in 
6.7% of patients receiving eculizumab vs. 35.7% of 
those who received no anti-C5 therapy. Eculizumab 
is not licensed for the treatment of AMR (indications 
include paroxysmal nocturnal haemoglobinuria and 
atypical haemolytic-uremic syndrome (HUS)). High 
cost (6,000 USD per one 300 mg vial) is another 
limitation for more widespread use.
Complement C1 Inhibitor
Another promising drug is the recombinant human 
complement C1 inhibitor (rhC1INH). It is presumed 
to inhibit the initial stage of complement activation 
via the classical pathway. The efficacy in preventing 
AMR has been demonstrated in chimpanzees. Phase 
I/II clinical trials are ongoing.23
Bortezomib
The largest number of recent literature reports 
concerning the treatment of AMR focus on 
bortezomib, a drug that targets plasma cells. 
Bortezomib is a small molecule, a tripeptide 
with an incorporated boron atom, which binds 
specifically to 26S proteasome. Bortezomib is a 
selective, reversible inhibitor of proteasome, an 
organelle containing proteases, whose role is the 
breakdown of proteins used throughout the cell’s 
life cycle. Bortezomib inhibits the breakdown of 
pro-apoptotic factors and the cell is destroyed via 
the programmed cell death mechanism (apoptosis). 
The NFκB pathway plays a key role in the survival 
of memory B cells and long-lived plasma cells. NFκB 
pathway activation is controlled by the breakdown 
of its inhibitor (IκB) by the proteasome complex, and 
conversely, the suppression of NFκB is maintained 
by high levels of IκB induced by bortezomib. 
Bortezomib causes plasma cell depletion, thus 
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synthetised in 1995, and obtained FDA approval for 
the treatment of multiple myeloma in 2003. It is 
available as intravenous formulation. The product is 
80% protein-bound, undergoes hepatic metabolism, 
with a half-life of 9-15 hours. The dosing is 1.3 mg/
m2/dose, four doses (day 1, 4, 7, 11). Major adverse 
effects include peripheral neuropathy (30% of 
patients), thrombocytopoenia and neutropoenia.24 
Everly et al.25 demonstrated the efficacy of 
bortezomib in six kidney transplant recipients with 
recurrent AMR. Trivedi et al.26 described the use of 
bortezomib in the protocol of tolerance induction 
in 11 living donor kidney graft recipients. Flechner et 
al.27 used bortezomib (in combination with PP and 
IVIg) for the treatment of AMR in 20 recipients and 
obtained 85% graft survival after 10 months, 50% 
reduction in DSA, and significant effectiveness in 
the subgroup with better baseline kidney function 
(creatinine <30 mg/dL). Walsh et al.28 showed better 
efficacy of bortezomib in early (<6 months) AMR 
in 13 kidney transplant recipients, as compared to 
17 late AMR events; superiority manifested by a 
greater DSA reduction and improved morphological 
aspect of the graft. Waiser et al.29 compared the 
outcomes of AMR therapy with bortezomib (1.3 mg/
m2 IV, day 1, 4, 8, 11) in 10 recipients with historical 
controls (9 patients who received a single dose of 
rituximab 500 mg) (all patients were given IVIg 30 
g), and demonstrated a significantly higher efficacy 
of bortezomib at 18 months follow-up (graft loss 
4/10 vs. 8/9). These preliminary results investigating 
the efficacy of bortezomib in the treatment of AMR 
are encouraging, but the outcomes of ongoing 
prospective randomised clinical trials are necessary 
to confirm them.
Splenectomy
The spleen is the largest lymphatic organ in 
humans and plays a major role in the production of 
alloantibodies. Splenectomy results in elimination of 
both precursor and mature DSA-producing plasma 
cells. The efficacy of splenectomy as rescue therapy 
for isolated cases of severe refractory AMR has 
been reported, however, due to the risk of infectious 
complications and the risk of surgery, it is not 
routinely recommended for the treatment of AMR.30
Chronic AMR
Risk factors for the development of chronic 
antibody-mediated rejection include acute AMR and 
pre-transplant immunisation. Hence, it is important 
to identify patients at high immunological risk, 
who are most likely to develop both acute and 
chronic antibody-mediated rejection. In chronic 
AMR, complement activation causes subclinical 
endothelial injury. However, slow immunological 
reaction leads inevitably to irreversible graft 
damage. Graft glomerulopathy being irreversible in 
the advanced stages, early detection of changes by 
DSA monitoring and protocol biopsies in high risk 
patients is justified. Theoretically, all acute AMR 
therapies could be useful in the treatment of chronic 
AMR, but there are practically no reports based on 
clinical trial evidence. IVIg, rituximab or bortezomib 
have been used in isolated cases. Therapies requiring 
continuous, repeated use, such as PP or eculizumab, 
are of limited value due to their high cost. Since 
TG-related changes are irreversible, the use of toxic 
therapies in chronic AMR cannot be justified as long 
as their efficacy is not confirmed in clinical trials. 
Preventing the development of AMR by adequate 
immunosuppression involving GS, tacrolimus and 
mycophenolate mofetil and monitoring of graft 
recipient is the key element.
CONCLUSION
To conclude, antibody-mediated rejection is 
relatively uncommon in kidney transplant recipients, 
but the risk of graft loss is high. Recently several 
promising therapies have emerged, most of 
them targeting B lymphocytes, plasma cells and 
complement (rituximab, bortezomib, eculizumab), 
but their efficacy should be confirmed in randomised 
clinical trials. Currently there is a risk of unjustified 
polypharmacy, severe infectious complications 
and high costs.31 There is no single recommended 
regimen for the treatment of AMR. Many authors 
suggest to start with glucocorticoid pulses and 
primary immunosuppression involving prednisone, 
tacrolimus and MMF. First-line therapy consists in PP 
with IVIg 100 mg/kg bw (targeting 1 g/kg bw) after 
each PP session. If this proves ineffective, second-
line therapy may involve rituximab (a single dose 375 
mg/m2) or bortezomib (four doses; 1.3 mg/m2/dose), 
each dose preceded by plasmapheresis. Eculizumab 
or splenectomy may be considered as rescue therapy. 
DSA should be monitored weekly for 4-12 weeks, 
then once a month for 3 months. Increase in DSA 
levels is an indication for a repeat graft biopsy. Anti-
thymocyte serum may prove effective in the presence 
of a steroid-resistant cellular rejection component.32 
These novel therapies cannot be used in Poland, as 
drugs such as eculizumab, bortezomib or rituximab 
are not licensed for use in transplantology.NEPHROLOGY  •  July 2013    EMJ EUROPEAN MEDICAL JOURNAL 45
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